New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CAT;IQNT;GRMN;JCP;JNJ;KRC;NKTR;STRA;VRTX;VNO;BMY;PBR;HES From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
May 18, 2015
16:00 EDTPBROptions Update; May 18, 2015
Subscribe for More Information
10:01 EDTHES, PBROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:36 EDTPBRActive equity options trading on open
Subscribe for More Information
06:44 EDTHESHess Corp. downgraded to Neutral from Buy at Goldman
Goldman downgraded Hess to Neutral and lowered its price target to $68 from $80 based on reduced upside from lower oil/gas price forecasts.
06:18 EDTPBRPetrobras downgraded to Sell from Neutral at Goldman
Goldman downgraded Petrobras to Sell and reduced its price target to $5.10 from $6.30 based on year-to-date performance vs. lower Brent prices and a reduced oil growth forecast.
May 17, 2015
13:46 EDTVRTXVertex reports Orkambi data, says 'significant improvements' in primary endpoint
Vertex Pharmaceuticals announced that the New England Journal of Medicine published data from the two phase 3 studies of Orkambi, or lumacaftor/ivacaftor, a medicine designed to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation. In November 2014, Vertex submitted an NDA to the FDA for the combination of lumacaftor and ivacaftor. On May 12th, the FDA’s Pulmonary Allergy Drugs Advisory Committee voted 12-1 to recommend approval of Orkambi for people ages 12 and older with two copies of the F508del mutation. The FDA is expected to make a decision by July 5. The New England Journal reports that the studies enrolled 1108 patients who underwent randomization and received Orkambi. In both studies, there were significant improvements in the primary end point in both lumacaftor–ivacaftor dose groups. The difference between active treatment and placebo with respect to the mean absolute improvement in the percentage of predicted FEV ranged 2.6%-4%, which corresponded to a mean relative treatment difference of 4.3 to 6.7%. Pooled analyses showed that the rate of pulmonary exacerbations was 30%-39% lower than in the placebo group. The rate of events leading to hospitalization or the use of intravenous antibiotics was also lower. The incidence of adverse events was generally similar to the placebo group.
May 15, 2015
10:12 EDTCATJPMorgan says sell Deere ahead of potential liquidity crunch for farmers
Subscribe for More Information
10:01 EDTJCPOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Aspen Technology (AZPN) upgraded to Overweight from Sector Weight at Pacific Crest... Canadian National (CNI) upgraded to Outperform from Sector Perform at Scotia Capital... Connecticut Water (CTWS) upgraded to Outperform from Market Perform at Wells Fargo... Hanesbrands (HBI) upgraded to Buy from Neutral at DA Davidson... Impala Platinum (IMPUY) upgraded to Buy from Neutral at Goldman... Inovalon (INOV) upgraded to Buy from Neutral at Goldman... J.C. Penney (JCP) upgraded to Market Perform at BMO Capital... Sovran Self Storage (SSS) upgraded to Buy from Neutral at UBS... Syngenta (SYT) upgraded to Neutral from Underperform at Exane BNP Paribas... UPS (UPS) upgraded to Buy from Neutral at Goldman... Union Pacific (UNP) upgraded to Buy from Hold at TD Securities... Yum! Brands (YUM) upgraded to Overweight from Neutral at JPMorgan.
09:31 EDTVRTXAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
07:35 EDTJNJMedivation price target raised to $148 from $128 at Leerink
Subscribe for More Information
07:14 EDTJCPJ.C. Penney upgraded to Market Perform at BMO Capital
Subscribe for More Information
07:05 EDTJCPJ.C. Penney upgraded to Market Perform from Underperform at BMO Capital
Subscribe for More Information
06:27 EDTGRMNCiti calls Garmin risk/reward unattractive, reiterates Sell
Citigroup says that around $46, shares of Garmin are unattractive on a risk/reward basis. In a bear case scenario, Citi believes the stock is worth $32. In a bull case, the firm thinks the shares are worth $52. It reiterates a Sell rating on Garmin with a $42 price target.
May 14, 2015
16:19 EDTJCPOn The Fly: Top stock stories for Thursday
Subscribe for More Information
16:00 EDTJCPOptions Update; May 14, 2015
Subscribe for More Information
14:54 EDTJNJJohnson & Johnson unit reports results of VENTURE-AF trial
Subscribe for More Information
12:55 EDTJCPBulls, bears debate J.C. Penney after earnings report
Subscribe for More Information
11:03 EDTBMYBristol-Myers treatment of progressive supranuclear palsy granted orphan status
Subscribe for More Information
10:41 EDTBMYAnalysts upbeat on Amgen's Kyprolis after ASCO abstracts
Subscribe for More Information
09:41 EDTJNJLeerink medical devices analyst holds a cardiology luncheon meeting
Subscribe for More Information
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use